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Background
Progression to AIDS and loss of CD4+ T cells are associ-
ated with a decline in antibody titers to the viral Gag pro-
tein, while anti-Env antibodies remain high, suggesting a
T cell independent antibody response to Env.
Methods
To test this hypothesis, immunocompetent Balb/c and T-
cell deficient nude mice were immunized with non-infec-
tious virus-like particles (VLP) of simian immunodefi-
ciency virus or adenoviral vectors expressing Gag and Env.
In addition, B-cells from primed Balb/C mice were trans-
fered into nude mice, to evaluate T-cell dependance of sec-
ondary antibody responses.
Results
High levels of antibodies against Gag and Env could only
be induced in immunocompetent mice, but not in the
immunodeficient mice. Thus, neither cells expressing Env
after adenoviral gene transfer nor VLPs induce a T cell
independent primary anti-Env antibody response. How-
ever, secondary B cell responses to Env, but not to Gag,
were observed in immunodeficient mice after transfer of
primed B-cells and boosting with VLPs. These T-cell inde-
pendent secondary antibody levels to Env were lower after
stimulation with VLPs modified to contain monomeric
membrane bound gp130 and undetectable after injection
of soluble gp130.
Conclusion
Membrane-bound trimeric Env seems to be responsible
for maintenance of high levels of anti-Env antibodies dur-
ing progression to AIDS. This T-cell independent second-
ary antibody response might contribute to viral immune
escape by favoring persistence of non-inhibitory antibod-
ies due to competition with T-cell-dependent affinity mat-
uration.
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